ALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INC

ALNYLAM PHARMACEUTICALS INC

No trades
See on Supercharts
Next report date
Report period
Q2 2024
EPS estimate
−0.96EUR
Revenue estimate
‪423.09 M‬EUR
Market capitalization
‪17.70 B‬EUR
−3.20EUR
‪−398.86 M‬EUR
‪1.66 B‬EUR
‪125.76 M‬
Beta (1Y)
1.27

About Alnylam Pharmaceuticals, Inc.

CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Employees (FY)
‪2.1 K‬
Founded
2002
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where DUL is featured.

Frequently Asked Questions

The current price of DUL is 141.80 EUR — it has increased by 0.93% in the past 24 hours. Watch ALNYLAM PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ALNYLAM PHARMACEUTICALS INC stocks are traded under the ticker DUL.
ALNYLAM PHARMACEUTICALS INC is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
DUL stock is 1.00% volatile and has beta coefficient of 1.27. Track ALNYLAM PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is ALNYLAM PHARMACEUTICALS INC there?
DUL earnings for the last quarter are −1.00 EUR per share, whereas the estimation was −1.07 EUR resulting in a 7.28% surprise. The estimated earnings for the next quarter are −1.03 EUR per share. See more details about ALNYLAM PHARMACEUTICALS INC earnings.
ALNYLAM PHARMACEUTICALS INC revenue for the last quarter amounts to ‪398.39 M‬ EUR despite the estimated figure of ‪395.85 M‬ EUR. In the next quarter revenue is expected to reach ‪396.67 M‬ EUR.
Yes, you can track ALNYLAM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
DUL stock has risen by 5.47% compared to the previous week, the month change is a 0.89% rise, over the last year ALNYLAM PHARMACEUTICALS INC has showed a 21.92% decrease.
DUL net income for the last quarter is ‪−61.11 M‬ EUR, while the quarter before that showed ‪−124.91 M‬ EUR of net income which accounts for 51.08% change. Track more ALNYLAM PHARMACEUTICALS INC financial stats to get the full picture.
Today ALNYLAM PHARMACEUTICALS INC has the market capitalization of ‪17.73 B‬, it has decreased by 1.45% over the last week.
No, DUL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
DUL reached its all-time high on Aug 16, 2022 with the price of 230.15 EUR, and its all-time low was 80.69 EUR and was reached on Mar 13, 2020. View more price dynamics on DUL chart.
See other stocks reaching their highest and lowest prices.
As of May 3, 2024, the company has ‪2.10 K‬ employees. See our rating of the largest employees — is ALNYLAM PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALNYLAM PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALNYLAM PHARMACEUTICALS INC stock shows the sell signal. See more of ALNYLAM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ALNYLAM PHARMACEUTICALS INC future price: according to them, DUL price has a max estimate of 368.36 EUR and a min estimate of 128.69 EUR. Watch DUL chart and read a more detailed ALNYLAM PHARMACEUTICALS INC stock forecast: see what analysts think of ALNYLAM PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACEUTICALS INC EBITDA is ‪−113.34 M‬ EUR, and current EBITDA margin is −12.48%. See more stats in ALNYLAM PHARMACEUTICALS INC financial statements.